Type 1 or 2 diabetes requiring anti-hyperglycemic medication (e.g. metformin, glipizide, insulin)
Patients currently taking metformin will be eligible
Patients may not be taking metformin for a reason other than study participation
Patients must not receive metformin for at least 5 days prior to enrollment and for the duration of study treatment
Subjects may have diabetes mellitus but must not be taking metformin
Known hypersensitivity or intolerance to metformin
Known hypersensitivity to metformin
Subjects currently treated with metformin and/or bicalutamide or who have been treated with metformin and/or bicalutamide in the past 6 months
Prior or current use of metformin within the past 3 months
History of hypersensitivity to metformin or history of discontinuation secondary to attributed adverse effects
Chronic (daily use for > 1 month) use of cimetidine (significant increase in metformin concentration and risk of lactic acidosis)
Iodinated contrast agents used in prior 48 hours (significant increase in metformin concentration and risk of lactic acidosis)
Subjects receiving metformin or other agents known to increase risk of lactic acidosis.
Subjects may have diabetes mellitus but must not be taking metformin or have previously taken metformin within previous year
Known hypersensitivity or intolerance to metformin
Subjects who are pregnant or breastfeeding, or may become pregnant during metformin and doxycycline administration
Subjects on metformin or doxycycline for any reason during the preceding 4 weeks
Diabetic subjects that are managed by taking metformin or insulin
Subjects who have received iodinated contrast dye must wait 12 hours prior to starting metformin; if a computed tomography (CT) scan with contrast is scheduled after screening and consent, the metformin cannot be taken until after the CT with contrast has been completed and they have waited 12 hours
Patient with prior allergic reaction to metformin, doxycycline, or any other tetracycline antibiotic in the past
Patient is on medications that are contraindicated with metformin or doxycycline under current Food and Drug Administration (FDA) recommendations; the following is a list of medications identified as class D (consider therapy modification) when treatment with metformin or doxycycline is considered:\r\n* Class D:\r\n** Bismuth Subsalicylate\r\n** Cimetidine\r\n** Iodinated contrast agents\r\n** Somatropin
Both arms: patients should not have received metformin within 6 months prior to registration\r\n* Arm B: patients who were on metformin while on PD-1/PD-L1 inhibitors are not eligible
Patients with known diabetes whose glucose control or general health condition may be adversely affected by the use of metformin as per the study protocol as deemed by either the study investigator or endocrinologist are excluded
Patients must not have any of the following contraindications to metformin:\r\n* Hypersensitivity to metformin or any component of the formulation\r\n* Kidney dysfunction or abnormal creatinine (Cr < 2 ng/mL) from any cause\r\n* Acute or metabolic acidosis
Patients must be at least 5 half-lives beyond previous treatment with metformin and currently not taking metformin
History of hypersensitivity to TAK-228 or metformin
Subjects who are pregnant or breastfeeding or may become pregnant during metformin and doxycycline administration
Subjects on metformin or doxycycline for any reason during the preceding 4 weeks
Diabetic subjects are eligible if they are not taking metformin or insulin
Subjects who have received iodinated contrast dye must wait 12 hours prior to starting Metformin; if a computed tomography (CT) scan with contrast is scheduled after screening and consent, the metformin cannot be taken until after the CT with contrast has been completed and they have waited 12 hours
Prior allergic reaction to metformin, doxycycline, or any other tetracycline antibiotic in the past
Patient is on medications that are contraindicated with metformin or doxycycline under current Food and Drug Administration (FDA) recommendations; the following is a list of medications identified as class D (consider therapy modification) when treatment with metformin or doxycycline is considered\r\n* Class D \r\n** Bismuth Subsalicylate\r\n** Cimetidine\r\n** Iodinated contrast agents\r\n** Somatropin
No previous treatment with vandetanib; previous or ongoing treatment with metformin is allowed
Known serious allergic reaction to vandetanib or metformin
Known sulfonylurea treatment within 7 days prior to registration; sulfonylureas include glyburide/glibenclamide (Diabeta, Glynase); glyburide plus metformin (Glucovance); glimepiride (Amaryl); repaglinide (Prandin); nateglinide (Starlix); glipizide (Glucotrol, GlibeneseR, MinodiabR); gliclazide (DiamicronR); tolbutamide (Orinase, Tolinase); and glibornuride (Glutril)
Patients who are currently taking metformin; prior metformin use is allowed if last dose was 3 months previous to this trial
History of allergic reactions attributed to metformin or other biguinides
Currently taking metformin, sulfonyureas, thiazolidenediones or insulin for any reason
History of hypersensitivity to temsirolimus or metformin
Subjects with known diabetes and those taking metformin, sulfonylureas, thiazolidinediones or insulin for any reason
Patients with diabetes on metformin; patients with diabetes and not on metformin will be eligible if it is deemed safe after consultation with the patient physician managing diabetes
Patients taking metformin or digoxin
Patients currently using metformin (metformin hydrochloride), other oral hypoglycemic agents or insulin
Patients must NOT be taking metformin or have been on metformin in the past 6 months
Diabetic patients who are on metformin are eligible as long as they have been on metformin for less than 6 months (estimated 6 months or less duration of metformin therapy from start of metformin to enrollment on study)
Current use of metformin for more than 6 months prior to enrollment on study
Patients with type II diabetes currently already on metformin
Patients who received aspirin or metformin within the past 28 days
Patients taking medications with known interactions with metformin or aspirin
Patients with history of allergic reaction to metformin
Currently taking metformin, sulfonylureas, thiazolidinediones, or insulin for any reason
Have no contraindications to short-term metformin therapy
Need to be able to undergo metformin treatment for a duration of 12 weeks (+/- 7 days) prior to repeat endometrial biopsy
Are currently taking metformin or have taken metformin in the past 6 months or have a history of an allergic reaction or intolerance at any time to metformin
Are taking a drug that may significantly interact or influence the metabolism of metformin
Prior metformin treatment OR EGFR targeted therapy
Patients taking Metformin for any reason within 30 days of enrollment to the study
Subjects who are pregnant or may become pregnant during metformin administration
Subjects on metformin for any reason during the preceding 4 weeks
Diabetic subjects are eligible if they are not taking metformin, insulin or sulfonylureas
Subjects who have received iodinated contrast dye less than 48 hours prior to screening meet a temporary exclusion criteria to receive metformin; these patients cannot start investigational metformin until 48 hours have elapsed from contrast administration; subjects who are scheduled for iodinated contrast dye administration within 48 hours of definitive surgery are excluded
Currently taking metformin, sulfonylureas, thiazolidinedione, insulin, or other antidiabetic drugs for any reason
Known hypersensitivity or intolerance to metformin
Patients already receiving metformin or anti-diabetic medications are INELIGIBLE
If any patient develops symptomatic diabetes requiring drug therapy, he must receive such a therapy, which may include metformin; this must be documented, and the patient will not continue on the study
Metformin use in the last 6 months
A known hypersensitivity to metformin
Known intolerance to doxorubicin, metformin, or vincristine
Patients who have a need to continue hydroxyurea while on study\r\n* Please note: patients may continue on hydroxyurea only until the first dose of metformin is to be given
Known hypersensitivity to metformin or statins
Patients currently treated with metformin or a statin or who have been treated with metformin or a statin in the past 6 months are ineligible for this study
Subjects who are pregnant or may become pregnant during metformin administration in accordance with radioactive iodine treatment guidelines
Subjects on metformin for any reason during the preceding 4 weeks
Diabetic subjects are eligible if they are not taking metformin, insulin or sulfonylureas
Subjects who have received iodinated contrast dye; metformin treatment can be started the day after subjects complete iodinated contrast treatment; if a computed tomography (CT) scan with contrast is scheduled after screening and consent, the metformin treatment should be stopped the day before iodinated contrast administration; metformin can be resumed on the day after last iodinated contrast was administered to the subject
All medications other than those that may cause myelosuppression are permitted except those that are contraindicated with metformin under current Food and Drug Administration (FDA) recommendations
Current metformin therapy
Subjects who are pregnant or may become pregnant during metformin administration; pregnancy testing will be done in conjunction with preradiation protocols
Subjects on metformin for any reason during the preceding 4 weeks
Diabetic subjects are eligible if they are not taking metformin or insulin
Subjects who have received iodinated contrast dye must wait 12 hours prior to starting metformin; if a computed tomography (CT) scan with contrast is scheduled after screening and consent, the metformin cannot be taken until after the CT with contrast has been completed and they have waited 12 hours
All medications are permitted except those that are contraindicated with metformin under current Food and Drug Administration (FDA) recommendations
Known hypersensitivity or intolerance to metformin
Patients currently receiving or scheduled to receive a chemotherapy infusion other than adriamycin/cyclophosphamide prior to initiation of the metformin adaptation phase are not eligible; patients who are receiving adriamycin/cyclophosphamide must be scheduled to be at least 8 days post-chemotherapy infusion prior to initiation of the metformin adaptation phase in order to be eligible
Patients who are currently using metformin (eg, Fortamet, Glucophage, Glucophage XR, Glumetza, Riomet)
Contraindication to metformin prevention such as acute hypersensitivity or allergic reaction to metformin
Women who have taken metformin within the past 90 days
Current use of any drug (except metformin) or anticipated change in concomitant medication, which the investigator’s opinion could interfere with the glucose metabolism (e.g. systemic corticosteroids).
Currently taking medication that may impact weight (e.g., Synthroid, metformin)
Current or prior regular use of metformin within the past 3 months
History of allergic reactions attributed to compounds of similar chemical composition to metformin or prior use of metformin within the last year
Current use of metformin or other anti-diabetic agents, or hypersensitivity or allergy to metformin
VITAMIN D/METFORMIN SUBARM OF LOW GRADE DYSPLASIA/NO DYSPLASIA ARM:
VITAMIN D/METFORMIN SUBARM OF THE DYSPLASIA/NO DYSPLASIA ARM:
Allergic reaction to metformin
Participants may not be using metformin, cimetidine (Tagamet), furosemide (Lasix), nifedipine (Cardizem), or any other drug contraindicated for use with metformin
Have a history of allergic reactions to metformin or similar drugs
No known hypersensitivity or intolerance to metformin
No current treatment with metformin, sulfonylureas, thiazolidinediones or insulin for any reason
Prior treatment with metformin
Known allergy to metformin or other biguanide (Proguanil)
Participants who are taking metformin at the time of the exam are excluded
Taking metformin (example: Glucophage, Glucovance, Avandamet, Metaglip)
Currently taking Glucophage or Glucovance (metformin)
NORMAL VOLUNTEERS: Be taking metformin, aminoglycosides, other nephrotoxic medications, or daily use of NSAIDs
Patients with type 2 diabetes mellitus (T2DM) being treated with metformin (any dose) for a clinical indication at the time of study enrollment are eligible, and will continue metformin treatment as clinically indicated during the presurgical study period. Their dose of metformin will NOT be changed
Patients not on metformin at the time of study entry must be willing to take metformin extended release (Glucophage XR, 750 mg QD for 4 days, then 750 mg BID for 3-6 days) for a total of 7-10 days prior to surgery\r\n* Patients do not require a diagnosis of diabetes to be enrolled in the study
All patients must be willing to keep a drug diary indicating the dates and times of metformin administration
History of diabetes that is currently being treated without metformin
Patients who, at the time of study entry, are not taking metformin for a clinical indication, and who will need a radiographic analysis with an iodinated contrast agent during the metformin study treatment period
This criterion does not apply to patients taking clinically indicated metformin at the time of study entry
Known hypersensitivity to metformin
Must have been off metformin for at least 2 weeks prior to starting IFN gamma
Participants who are already on treatment with metformin, except when metformin can be held for 4 weeks prior to the start of the study
Diabetic patients are eligible but will be excluded if they are taking metformin, insulin or sulfonilureas
